Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : email@example.com
DF9001 is a tri-specific natural killer cell engager therapy that binds to tumor-expressed EGFR and NK cells, potentially inducing an anti-tumor immune response against EGFR-expressing tumor cells (NCI Drug Dictionary).
|CAS Registry Number||NA|
|Therapy Name||Drugs||Efficacy Evidence||Clinical Trials|
|DF9001 + Nivolumab||DF9001 Nivolumab||0||1|